target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id GPR139,130,Q6DWJ6,Human,L-tryptophan,717,,6305,OC(=O)[C@H](Cc1c[nH]c2c1cccc2)N,"InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1",QIVBCDIJIAJPQS-VIFPVBQESA-N,Agonist,Agonist,,yes,yes,,pEC50,,3.66,,EC50,,220000.0,,=,,,,24826842, GPR139,130,Q6DWJ6,Human,L-tryptophan,717,,6305,OC(=O)[C@H](Cc1c[nH]c2c1cccc2)N,"InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1",QIVBCDIJIAJPQS-VIFPVBQESA-N,Agonist,Agonist,,yes,yes,,pIC50,,4.59,,IC50,,26000.0,,=,Measured using a GTPγS assay in transfected COS7 cells.,,,26349500, GPR139,130,Q6DWJ6,Human,L-tryptophan,717,,6305,OC(=O)[C@H](Cc1c[nH]c2c1cccc2)N,"InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1",QIVBCDIJIAJPQS-VIFPVBQESA-N,Agonist,Agonist,,yes,yes,,pKi,,3.13,,Ki,,738000.0,,=,Inhibition equilibrium constant from a radioligand membrane binding assay.,,,26349500, GPR139,130,Q6DWJ6,Human,L-phenylalanine,3313,,6140,N[C@H](C(=O)O)Cc1ccccc1,"InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1",COLNVLDHVKWLRT-QMMMGPOBSA-N,Agonist,Agonist,,yes,yes,,pEC50,,3.49,,EC50,,320000.0,,=,,,,24826842, GPR139,130,Q6DWJ6,Human,L-phenylalanine,3313,,6140,N[C@H](C(=O)O)Cc1ccccc1,"InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1",COLNVLDHVKWLRT-QMMMGPOBSA-N,Agonist,Agonist,,yes,yes,,pIC50,,4.51,,IC50,,31000.0,,=,Measured using a GTPγS assay in transfected COS7 cells.,,,26349500, GPR139,130,Q6DWJ6,Human,L-phenylalanine,3313,,6140,N[C@H](C(=O)O)Cc1ccccc1,"InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1",COLNVLDHVKWLRT-QMMMGPOBSA-N,Agonist,Agonist,,yes,yes,,pKi,,3.06,,Ki,,872000.0,,=,Inhibition equilibrium constant from a radioligand membrane binding assay.,,,26349500, GPR139,130,Q6DWJ6,Human,compound 1a [PMID: 24900311],7799,,86277840,COc1cc(OC)cc(c1)C(=O)NNC(=O)Nc1ccc2c(c1)cccc2,"InChI=1S/C20H19N3O4/c1-26-17-10-15(11-18(12-17)27-2)19(24)22-23-20(25)21-16-8-7-13-5-3-4-6-14(13)9-16/h3-12H,1-2H3,(H,22,24)(H2,21,23,25)",IFQNPGNCFXITTG-UHFFFAOYSA-N,Agonist,Full agonist,,,,,pEC50,,7.41,,EC50,,39.0,,=,,,,24900311, GPR139,130,Q6DWJ6,Human,JNJ-63533054,8766,,2548547,O=C(N[C@H](c1ccccc1)C)CNC(=O)c1cccc(c1)Cl,"InChI=1S/C17H17ClN2O2/c1-12(13-6-3-2-4-7-13)20-16(21)11-19-17(22)14-8-5-9-15(18)10-14/h2-10,12H,11H2,1H3,(H,19,22)(H,20,21)/t12-/m0/s1",MWDVCHRYCKXEBY-LBPRGKRZSA-N,Agonist,Agonist,,,yes,,pKi,,7.62,,Ki,,24.0,,=,,,,26349500, GPR139,130,Q6DWJ6,Human,LP-360924,8773,,91938092,COCCCNc1nc(Nc2nc(c(s2)C(=O)N2CCN(CC2)c2ncccn2)c2ccccc2)nc(n1)OC,"InChI=1S/C26H30N10O3S/c1-38-17-7-12-27-22-31-23(33-25(32-22)39-2)34-26-30-19(18-8-4-3-5-9-18)20(40-26)21(37)35-13-15-36(16-14-35)24-28-10-6-11-29-24/h3-6,8-11H,7,12-17H2,1-2H3,(H2,27,30,31,32,33,34)",OIRCJRUZRVLDFA-UHFFFAOYSA-N,Agonist,Agonist,,,,,,,,,,,,,=,,,,19525486, GPR139,130,Q6DWJ6,Human,LP-471756,8774,,789353,Cc1ccccc1NS(=O)(=O)c1ccc(cc1)C1CCCCC1,"InChI=1S/C19H23NO2S/c1-15-7-5-6-10-19(15)20-23(21,22)18-13-11-17(12-14-18)16-8-3-2-4-9-16/h5-7,10-14,16,20H,2-4,8-9H2,1H3",STLMNZVBCJVQOZ-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.19,,IC50,,640.0,,=,,,,19525486, GPR139,130,Q6DWJ6,Human,NCRW0005-F05,8775,,5017692,COc1ccc(cc1)C1N(c2ccccc2)C(=O)C1(F)F,"InChI=1S/C16H13F2NO2/c1-21-13-9-7-11(8-10-13)14-16(17,18)15(20)19(14)12-5-3-2-4-6-12/h2-10,14H,1H3",AIIIYUSGINMZMS-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.68,,IC50,,210.0,,=,,,,26027661, GPR139,130,Q6DWJ6,Human,zelatriazin (TAK-041),11685,,121349608,O=c1c2c(nnn1CC(=O)N[C@@H](C)c1ccc(cc1)OC(F)(F)F)cccc2,"InChI=1S/C18H15F3N4O3/c1-11(12-6-8-13(9-7-12)28-18(19,20)21)22-16(26)10-25-17(27)14-4-2-3-5-15(14)23-24-25/h2-9,11H,10H2,1H3,(H,22,26)/t11-/m0/s1",JZGLECLGVQRPPI-NSHDSACASA-N,Agonist,Agonist,,,,,pEC50,,7.66,,EC50,,22.0,,=,"Agonist-induced in vitro calcium mobilization assay, using CHO-T-REx cells stably expressing hGPR139",,,34260228, GPR139,130,Q6DWJ6,Human,zelatriazin (TAK-041),11685,,121349608,O=c1c2c(nnn1CC(=O)N[C@@H](C)c1ccc(cc1)OC(F)(F)F)cccc2,"InChI=1S/C18H15F3N4O3/c1-11(12-6-8-13(9-7-12)28-18(19,20)21)22-16(26)10-25-17(27)14-4-2-3-5-15(14)23-24-25/h2-9,11H,10H2,1H3,(H,22,26)/t11-/m0/s1",JZGLECLGVQRPPI-NSHDSACASA-N,Agonist,Agonist,,,,,pKi,,6.92,,Ki,,119.0,,=,Radioligand competition binding assay using membranes isolated from CHO-T-REx cells that stably express the hGPR139,,,34260228, GPR139,130,Q6DWJ6,Human,NCRW0105-E06,12363,,5348723,Oc1cc2c(cc1)c(=O)c(c1ccc(Cl)cc1)c(o2)C(F)(F)F,"InChI=1S/C16H8ClF3O3/c17-9-3-1-8(2-4-9)13-14(22)11-6-5-10(21)7-12(11)23-15(13)16(18,19)20/h1-7,21H",LIVWZNRIYNUFRC-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.29,,IC50,,512.0,,=,Inhibition of Ca2+ mobilization,,,36736525,